Red Blood Cell Alloimmunization in Transfused Patients with Sickle Cell Disease in Sub-Saharan Africa; a Systematic Review and Meta-Analysis by Bates, Imelda
Accepted Manuscript
Red Blood Cell Alloimmunization in Transfused Patients with
Sickle Cell Disease in Sub-Saharan Africa; a Systematic Review
and Meta-Analysis
Lilian Antwi Boateng, Alain M. Ngoma, Imelda Bates, Henk
Schonewille
PII: S0887-7963(19)30022-7
DOI: https://doi.org/10.1016/j.tmrv.2019.06.003
Reference: YTMRV 50577
To appear in: Transfusion Medicine Reviews
Please cite this article as: L.A. Boateng, A.M. Ngoma, I. Bates, et al., Red Blood Cell
Alloimmunization in Transfused Patients with Sickle Cell Disease in Sub-Saharan Africa;
a Systematic Review and Meta-Analysis, Transfusion Medicine Reviews, https://doi.org/
10.1016/j.tmrv.2019.06.003
This is a PDF file of an unedited manuscript that has been accepted for publication. As
a service to our customers we are providing this early version of the manuscript. The
manuscript will undergo copyediting, typesetting, and review of the resulting proof before
it is published in its final form. Please note that during the production process errors may
be discovered which could affect the content, and all legal disclaimers that apply to the
journal pertain.
AC
CE
PT
ED
 M
AN
US
CR
IP
T
Red blood cell alloimmunization in transfused patients with sickle cell 
disease in sub-Saharan Africa; a systematic review and meta-analysis 
Lilian Antwi Boateng
a,b
, Alain M. Ngoma
c 
, Imelda Bates
b
 and Henk Schonewille
d 
 
a
International Public Health, Liverpool School of Tropical Medicine, Liverpool, UK 
b
Medical Laboratory Technology, Kwame Nkrumah University of Science and Technology, Kumasi, 
Ghana
 
c
 Douglas Hospital Research Centre, McGill University, Montreal, Quebec, Canada 
d
Department of Experimental Immunohematology, Sanquin, Amsterdam, Netherlands 
 
Correspondence to: 
Lilian Antwi Boateng 
Liverpool School of Tropical Medicine 
Pembroke Place, L3 5QA, UK 
Tel: +44 7459662114 
Email: lilian.boateng@lstmed.ac.uk 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
Abstract 
Sickle cell disease (SCD) is the most common monogenic disorder in sub-Saharan Africa 
(SSA). Blood transfusion to increase the oxygen carrying capacity of blood is vital in the 
management of many patients with SCD. However, red blood cell (RBC) alloimmunization is 
a major challenge to transfusions in these patients. Commonly in SSA, pre-transfusion tests 
only involve ABO D grouping and compatibility without RBC antibody testing. Data on the 
frequency of RBC alloimmunization in patients with SCD in SSA is limited. We performed a 
systematic review and meta-analysis on available data on alloimmunization in transfused 
patients with SCD to determine the published prevalence of RBC alloimmunization in SCD 
patients in SSA.  
Six databases were systematically searched to identify relevant studies, without year or 
language restrictions.  In all, 249 articles were identified and 15 met our selection criteria.  
The overall proportion of alloimmunization was 7.4 (95% CI: 5.1 – 10.0), per 100 transfused 
patients. Antibodies against E, D, C and K antigens accounted for almost half of antibody 
specificities and antibodies to low and high frequency antigens were also common and 
represented almost 30% (20% to low frequency antigens and 9% to high frequency antigens) 
of specificities. Heterogeneity between studies was moderate and meta-analysis found region 
of Africa as the major contributor to the heterogeneity. We also observed inconsistencies 
across studies in reporting of factors that may influence alloimmunization. 
This review provides an overview of the extent of the alloimmunization problem in SSA and 
provides a baseline against which to compare the effect of any interventions to reduce the 
alloimmunization risk. 
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Introduction 
Sickle cell disease (SCD) is widely disseminated, affecting millions of people worldwide, 
primarily those of sub-Saharan African (SSA), South and Central American, Arabic, Indian, 
and Mediterranean descent, because of the protection the sickle cell trait offers against severe 
malarial infection [1]. It is the most common inherited genetic disorder in SSA, and SSA 
accounts for over 75% of the global SCD burden and with 50-90% mortality rate, especially 
among children up to age five [2]. The area of Africa that lies between latitude 15
0
 North and 
latitude 20
0
 South have the highest prevalence of the sickle cell trait, ranging from 10%-45% 
and up to 3% of all children are born with SCD [3-6].  
Although, in well-resourced countries, administration of hydroxyurea has improved patients’ 
outcome, blood transfusion therapy remains an important part of disease management to treat 
or prevent SCD related complications [7-9]. However, in SSA, blood transfusion presents 
major challenges, due to widespread blood shortages, the high cost and the risk of 
transfusion-transmitted infections. In view of this, transfusions in patients with SCD in SSA 
are reserved for life-threatening anemia and acute stroke management, mostly one unit of 
blood at a time. The number of blood donations in Africa increased by almost 50% between 
2008 and 2013 [10] alongside increased effort to reduce transfusion transmitted infections 
[11,12], which is likely to improve the safety and availability of transfusions for patients with 
SCD in SSA. 
Red blood cell (RBC) antibody formation (i.e. alloimmunization) against foreign RBC 
antigens, is a major complication in transfused patients with SCD and presents significant 
challenges in their management. Alloimmunization frequency of up to 76% has been reported 
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in patients with SCD [13-16]. Risk factors for alloimmunization are multifactorial including 
patients’ age, RBC antigen disparity, age of first transfusion, sex, number of RBC 
transfusions, race, age of RBCs transfused and patients’ genetic and inflammatory status [17-
23].  
RBC alloimmunization increases the risk of auto-immunization, hyperhaemolysis 
syndrome and delayed hemolytic transfusion reaction [24-30]. Measures to reduce RBC 
alloimmunization include transfusing donor blood for which the RBC antigens have been 
matched to that of the recipients (i.e. RBC antigen matching) and a judicious use of blood 
transfusions [16,31-33].   
Most studies reporting on RBC alloimmunization in patients with SCD have been 
conducted in well-resourced countries where pre-transfusion antibody screening and 
identification are routine practices. In resource-limited settings such as SSA, where antibody 
screening is not routinely performed, data on the prevalence of RBC alloimmunization in 
patients with SCD are very scarce. We performed a systematic review of the literature and a 
meta-analysis to determine the published prevalence of RBC alloimmunization in SCD 
patients in SSA.  
 
Methodology 
Inclusion criteria 
The review considered all primary peer reviewed studies on transfused patients with SCD in 
SSA, without restriction to year of publication, study design and language, that reported 
quantitative data on the prevalence of RBC alloimmunization and alloantibody specificities. 
Search strategy and study selection: 
The review was conducted following the PRISMA flow diagram (Figure 1) for selection of 
studies. Three search strategies were used to search for articles published up to February 
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2019. A search for articles, screening of the articles and data extraction were done 
independently by two authors (LAB and HS).  
The first step involved searching six databases (Medline, CINAHL, Web of Science, Google 
Scholar, PubMed, African Journals Online (AJOL) with specific search terms sickle cell 
disease, sickle cell anaemia, SCD, haemoglobin S disease, alloantibodies, allo-antibodies, 
isoimmunisation, isoantibodies, red cell alloantibodies, unexpected alloantibodies, irregular 
erythrocyte antibodies, alloimmunisation, alloimmunization, multiple transfusion, blood 
transfusion, erythrocyte transfusion, “sub-Sahara Africa”, Africa, Tanzania, Nigeria, Uganda, 
Mali, South Africa, Ghana, Cote d’Ivoire, Congo, Mozambique, Namibia, Sierra Leone, Low 
resource countries and developing countries. References were extracted into Endnote X8 and 
duplicates were removed. Articles retrieved from the search were screened by their titles to 
exclude those that were not relevant to the topic. Additional search terms discovered from the 
first search were used in a second search for articles that were not captured during the initial 
search. Resulting articles were screened by their abstracts to select articles that met the 
inclusion criteria. These articles were then assessed for eligibility by reading the full text by 
LAB, AMN and HS. Finally, references of selected articles were searched for any other 
articles relevant to the studies.  
 
Data extraction 
Data extraction was conducted independently by two investigators (LAB and HS) and 
discordances were resolved by discussion and consensus. Extracted data included study 
design, population under study, number of transfused patients, number of alloimmunised 
patients, and alloantibody specificities (Table 1). 
 
Quality assessment 
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The quality of each included study was independently assessed by two authors (LAB and 
AMN) discordances were resolved by discussion and consensus. The Standards for Reporting 
of Diagnostics accuracy (STARD) for diagnostic studies and criteria specific to prevalence 
studies was used [34]. The tool contained the following items: (1) definition of the outcome; 
(2) description of the selection criteria; (3) description of the study population; (4) type of 
study; (5) reference standard; (6) reported prevalence; and (7) reproducibility. The quality for 
each of the seven criteria was assessed as either ‘yes’ or ‘no’. All ‘yes’ scores were summed 
up. Studies were graded as: A, high quality (score of 7), B, moderate quality (score 4 to 6) or 
C, low quality (score <4) (Supplementary Table 1). 
 
Data synthesis and analysis 
For each study, the frequency of RBC alloimmunised patients were calculated as the reported 
numbers of patients with alloantibodies divided by the total number of patients tested for 
alloantibodies. Data were analyzed using the metaprop command of the meta package (4.9–2) 
in R (version 3.5.1) (R Foundation for Statistical Computing, Vienna, Austria) [35]. Random-
effects meta-analysis was performed, since variability in frequency estimates from different 
studies was expected. To minimize the influence from studies with extreme estimates on the 
overall estimate, proportions were transformed using the Freeman-Tukey double-arcsine 
transformation, which stabilized the variance of study-specific frequency and pooled within 
the DerSimonian and Laird using a random-effects model [36]. Heterogeneity in results 
across the studies was assessed using the I-squared (I
2
) statistic, considering as high 
heterogeneity when I
2
 was equal to or greater than 75% [37]. Meta-regression, using the 
metareg command was done to explore sources of heterogeneity and the univariable models 
were evaluated from the p-value for the test of moderators. A subgroup meta-analysis was 
performed based on significant variables. Publication bias was assessed with funnel plots of 
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study size against log [38]. A linear regression test was used to measure funnel plot 
asymmetry and a p value less than 0.05 was considered to be statistically significant. A leave-
one-out sensitivity analysis was performed to assess if our results were driven by any single 
study. 
 
Results 
Search results 
A total of 238 articles were identified in the initial search and 11 in the additional search. 
After removal of duplicates, 233 articles remained, and of these 16 met the inclusion criteria. 
Due to methodological flaws of one study [39], 15 studies were included in the review, 
thirteen were in the English and two in the French language  (Figure 1) [40-54].  
 
General study description 
The 15 studies were published between 2005 and 2019. Except for the retrospective study by 
Boma Muteb and collegues
41
, all others had a cross-sectional design, with regard to 
determination of alloimmunization frequency, and all were of moderate quality (i.e. score 4-
6). The studies were conducted in nine SSA countries. Between two and four studies were 
conducted in each of four countries. (Table 2). These ten studies were conducted in eight 
medical centers from different parts of the four countries. However, two studies from Nigeria 
[53,54] and the two studies from Cote d’Ivoire [47,48] were from the same medical centers. 
Although the study periods differed by about four years, patient overlap cannot be excluded.  
 
Prevalence of RBC alloimmunization 
Pooling of the 15 studies, with a cumulative sample size of 1994 participants, yielded an 
overall prevalence of 7.4 (95% CI: 5.1-10.0) per 100 participants (Figure 2). The 
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heterogeneity between studies was moderate (I
2
 = 71.7%; 95% CI, 52.3-83.7). Three studies 
[47,48,52] reported high prevalences of RBC alloimmunization (18.5-28.6%). Analysis 
revealed that these studies should be regarded as significant outliers. After excluding these 
three studies, the overall prevalence was 5.4 (95% CI: 4.2-6.8) per 100 participants and 
heterogeneity I
2
= 24% (95% CI, 0.0-61.2; p=0.21). 
 
Meta-regression subgroup analysis and sensitivity analysis  
The meta-regression analysis identified sub-region (West, East and Central Africa) (p<0.01) 
as the most significant contributor to the heterogeneity between studies. Subgroup analysis, 
after stratifying studies by sub-regions, showed that there was no heterogeneity in the five 
studies conducted in East Africa (I
2
 = 0%, p = 0.60) and a significant moderate heterogeneity 
in the eight studies from West Africa (I
2
 = 70%, p = 0.01) (Supplementary Table 2). The 
leave out sensitivity analysis indicated that no single study influenced the overall outcome 
nor heterogeneity (Supplementary Table 3). 
 
Publication bias 
Visually, the funnel plot looked symmetric (Figure 3) and the p value for Egger’s linear 
regression test was 0.86, indicating no evidence of publication bias.  
 
Description of methodologies used in the studies 
The sample size per study ranged from 27 to 428 transfused patients. Eight studies included 
only individuals with the SS genotype [40,41,43-46,53], five had a mixture of the SCD 
genotypes (i.e. SS, SC, Sthal) [47-50,54] and the remaining two [42,52] did not report on 
the SCD genotype of participants. While 13 studies included children and adults, Abbas [43] 
studied only children and Ugwu [53] only adults. Nine studies used the column gel technique 
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(CGA) [40,42,46-50,52-53] for antibody testing, three, the tube technique (TT) [43,45,54], 
one used both TT and CGA [51] and two studies did not report the antibody testing technique 
[41,44]. All screening and identification reagents were procured from international sources 
except for the studies performed by Sekongo [47] and Kaliyu [51], which utilized screening 
and/or identification cells produced at their centre. 
 
Transfusion History 
All study participants had received ABO-D compatible, non-leucocyte reduced transfusions. 
Generally, reports on the transfusion history of study participants were scanty; indication for 
transfusion, type of blood products (whole blood or RBC concentrates) and source of blood 
for transfusion (from related or non-related donors) were seldom reported. Some studies did 
not report mean (with standard deviation) or median (with range) number of transfused units 
[41,44,50,53]. For the 11 studies that reported these variables, the number of RBC units 
transfused per patient per study was generally low (mean 2.4 to 9.0 units, median 2-10, and 
ranged from 1-100). The indication for transfusion was only reported by four studies and 
anemia was the main indication [41, 42, 48, 54].  
 
Red blood cell antibody specificities 
Of the 1994 transfused patients, 136 patients had a total of 206 RBC antibodies. Antibody 
specificities could not be determined in 15 patients. Of these, three were pan-reactive and 
identity could not be ascertained for 12. At least, (because not all specificities were known 
for all patients), 35 (26%) patients had multiple antibody specificities. While antibodies were 
directed to antigens from ten blood group systems, 49% had D, C, E and K specificity. 
Antibodies against low frequency antigens (defined as present in <5% of population; i.e. C
w
, 
Go
a
, K, Kp
a
, M
g
, Vw, Lu
a
, Di
a
 and Wr
a
) and high frequency antigens (defined as present in 
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>95% of population; i.e. c, e, k, Kp
b
, Js
b
 and Lu
b
) reported for (African-American) Blacks 
[55] represented 20% and 9% of all specificities, respectively (Table 2).  
 
Discussion 
This systematic review identified and analyzed 15 cross-sectional studies on RBC 
alloimmunization in transfused patients with SCD from nine different SSA countries. The 
pooled prevalence of RBC alloimmunization was 7.4 (95% CI: 5.1-10.0, I
2
 = 71.7%) per 100 
transfused patients. Overall, antibodies against E, D, C and K antigens accounted for almost 
half of antibody specificities and antibodies to low and high prevalence antigens were also 
common and together represented almost 30% of specificities. Heterogeneity between studies 
was moderate and meta-regression found region of Africa as the major contributor to this 
heterogeneity. Data on factors that may influence alloimmunization such as the transfusion 
history and demographic characteristics of study participants were inconsistently reported 
across studies. 
As far as we know, this is the first systematic review and meta-analysis to provide an 
overview of the extent of alloimmunization in the transfused SCD population in SSA.  
In a recent review, performed in transfused patients in SSA, of which 31% were patients with 
SCD, the pooled prevalence of alloimmunization was 6.7% (95% CI: 5.7-7.8) which is 
comparable to our prevalence of 7.4% [56]. In well-resourced countries, the prevalence of 
alloimmunization has shown to be higher in patients with SCD than the other transfused 
population, partly because of patients’ specific inflammatory status and the likelihood of 
more RBC transfusions in their lifetime, associated with more allo-antigen exposure [13,23]. 
The latter may not hold true for patients with SCD from less well-resourced countries, 
because the majority of transfusions are reserved for severe life-threatening anemia in all 
patients, with and without SCD. In addition, because transfusion in SCD is common in well-
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resourced countries, antibody tests are performed more frequently, increasing the likelihood 
of antibody detection. 
In well-resourced countries, patients with SCD often receive transfusions for which RBC 
antigens are matched between patients and donors [57]. There have been proposals to apply 
this policy for patients with SCD in SSA, [43,47,51,53-54]. At present, this may not be 
feasible because 1) most transfusions are given in emergency situations, 2) the limited 
availability of donor blood in SSA and 3) the cost. However, since patients with SCD are 
likely to be multiply transfused a more pragmatic approach to increase safety would be to 
start with routine testing for RBC antibodies and indirect antiglobulin cross matching to 
select compatible units for transfusions. Patients who have already made antibodies could 
undergo additional matching, at least for Rh antigens, since these are the most immunogenic. 
 
RBC alloantibody specificity 
The observation that anti-E, -D, -C and -K represented almost 50% of antibody specificities 
in our review is comparable to alloimmunization rates reported among the general multi 
transfused patients in SSA [56] and in non-African countries, despite the frequent Rh and K 
antigen matched transfusions in the latter [58]. 
Even though matching for D antigen is routine in SSA, anti-D was present in our study in 22 
(10.7%) patients. While most studies did not report on the event (for example, pregnancy or 
previous transfusion) that led to anti-D production or the D-status of patients with anti-D, 
Natukunda et al., found that most of their Ugandan patients with anti D had RHD variants 
[45]. RHD variants have been reported to be common in individuals of African descent [59]. 
Patients with RHD variants (such as DAU3, DIIIa and DIVa) that are D-positive with 
serology, will receive D positive blood and are at risk of making anti D [60], although the 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
actual risk in these patients is unknown. In daily practice, the presence of RHD variants are 
most often found when D+ patients made anti-D.  
Twenty-one (15% of immunized) patients had anti K and 20 of these were from East-African 
studies. This may be explained by the variations in the frequency of the K-antigen in different 
parts in SSA and the associated risk for anti-K. Akasha  found the K antigen in 5.6% of 500 
random samples from a Sudanese population (East Africa) [61] whilst, studies in Nigeria  and 
Cote d’Ivoire, which are both in  West Africa, found lower frequencies, ranging from zero to 
2% [62-66]. 
The remarkably high percentage of antibodies against low and high frequency antigens 
observed in this review suggests that antigens categorized as low and high frequency in the 
Blacks, also mainly based on African American population, may not be readily extrapolated 
to the Black Africans [49]. In contrast to antibodies against high frequency antigens, 
antibodies against low frequency antigens are unlikely to cause transfusion problems with 
regard to finding compatible donors. However, because low-frequency antigens are generally 
not present on antibody testing cells, many antibodies will remain undetected and if clinically 
relevant, could cause hemolytic transfusion reactions [67,68]. Therefore, establishing the 
frequency of RBC antigens in Black Africans is imperative since it may influence the 
selection of antigens for RBC antibody testing panels for Africa.   
Overall, the variability in the prevalence and specificities of antibodies, highlights the need 
for more studies on blood group antigen diversity among different ethnic groups in SSA.  
Then, establishing a database of antigen typed blood donors would assist in the local 
manufacture of reagent red cells for antibody testing which would aid in the detection of 
antibodies to African antigens [69]. A locally manufactured reagent red cells would also 
decrease the dependence on internationally prepared reagent red cells which are not generally 
affordable in resource-limited SSA, thereby, providing an appropriate, sustainable and 
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economical means of RBC antibody testing in patients with SCD and other multi-transfused 
patients. 
 
Strengths and limitations of the review 
The literature search was exhaustive with no database, publication year or language 
restrictions and was performed independently by two researchers. In addition, the review 
identified studies from a range of countries. 
However, the findings of the studies should be interpreted in light of some limitations. First, 
14 of 15 studies were cross sectional, which probably under reported the frequency. At the 
time of sampling, probably less than one third of antibodies might have been detected, 
because, some antibody titres might have fallen not have reached, or may have fallen below, 
detectable levels [70]. Most of the studies had incomplete descriptions of sampling methods 
so it was not possible to tell whether studies involved a biased, and therefore potentially 
unrepresentative, population. The paucity of data (i.e. pregnancy, transfusion history, type 
and source of blood, period between last transfusion and antibody testing, etc) in many 
studies prohibited the analyses for risk factors for alloimmunization. 
 
Implication for transfusion practice and future research  
Consideration should be given to the incorporation of RBC antibody testing into routine pre-
transfusion screening procedures for patients with SCD and for blood banks to always 
perform complete (indirect antihuman globulin) cross-match prior to blood transfusion. 
Authors speculate that inconsistencies in reporting of patient characteristics in the included 
studies may be due to inadequate documentation at the participating hospitals. We therefore 
suggest the need for healthcare facilities in SSA to improve documentation of patients’ 
records to allow researchers to obtain accurate and up to date information on patients with 
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SCD. Major teaching hospitals in SSA could consider upgrading from manual entry of 
patients’ records to the use of a medical computerized program that electronically captures 
and manages patients’ records. This would not only help promote research in SSA but 
improve patient management. 
 
Studies are needed which report information on parameters that have been shown to influence 
alloimmunization risk such as sex, age of patients, number of transfusion events before 
alloimmunization occurred, history of pregnancy, age at first transfusion and age of RBCs 
transfused. 
The RBC antigen profile of blood donors and patients with SCD across different ethnic 
groups in SSA should be established. Then, studies to explore the feasibility of incorporating 
RBC antibody screening and identification tests using locally prepared reagent red cells 
(expressing ‘African antigens’) would be essential to identify the potential challenges to the 
incorporation of RBC antibody testing in SSA. Testing for RBC antibodies, preferably at 
fixed time points after transfusion, would aid in establishing the incidence and specificity of 
alloimmunisation in SSA more precisely. 
Strengthening of haemovigilance systems in SSA are important, to accurately document the 
incidence of post transfusion complications including acute and delayed hemolytic 
transfusion reactions [12,71]. This would help quantify the extent of the clinical 
consequences of alloimmunization in patients with SCD. 
 
Conclusion 
Findings of this review provide evidence that patients with SCD receiving blood transfusion 
in SSA are burdened with the development of RBC alloantibodies, although lower compared 
to those in well-resourced countries, where transfusions are given more frequently. However, 
in resource-limited settings such as SSA, implementation of RBC antigen matching for all 
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patients would be difficult. A practical approach would be to screen patients with SCD for 
RBC antibodies and perform a complete crossmatch prior to RBC transfusion to aid in the 
detection of potentially dangerous antibodies. Alloimmunised patients should be given blood 
that is antigen negative, at least for the antibodies they possess. Given that most transfusions 
are for acute situations, a database of antigen typed donors would be essential, for timely 
selection of compatible units. 
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Figure 1: Summary of data extraction history 
 
Figure 2: Forest plot of proportion estimates of RBC alloimmunisation in transfused patients with 
sickle cell disease, ranked from low to high number of total patients per study 
 
Figure 3: Funnel plot of sample size against log odds 
 
 
 
 
Table 1: Characteristics and outcomes of the 15 eligible cross-sectional studies from sub-Sahara 
Africa on red blood cell alloimmunization in transfused patients with sickle cell disease. 
First author  
(year of 
publication)
r
ef
 
Countr
y 
(region) 
N of 
Patients/ 
Transfuse
d patients 
Male 
to 
femal
e 
ratio 
Patien
t age 
(SD; 
range) 
RBCs 
transfuse
d 
(SD; 
range) 
Antibody 
test 
method 
N of 
Patients 
with allo-
antibodie
s  
(%; 95% 
CI) 
N of allo-
antibodies
:  
antibody 
specificitie
s 
Batina Agasa  
(2010)40 
Congo 
(Central
) 
144 / 127  1.26† Mean 
15.5 
(11.1; 
4-63) 
Mean 5.3 
(6.6; 1-
40) 
CGA-
LISS 
13  
(10.2; 
5.6-17) 
17: 3D, 
3C, 2E, 
9UI Boma Muteb 
(2017)41 
Congo 
(Central
) 
39 / 39 0.77 Mean 
8.  
(6.4;2-
27) 
82% >2 
units  
(NR; NR) 
NR 1 
(2.6; 0.1-
15.1) 
1: 1K 
Mangare  
(2015)42 
Kenya 
(East) 
137 / 137 0.99 Mean 
8 
(NR; 
1-36) 
Mean 2.4 
(NR; 1-8) 
CGA-
NaCl/LIS
S 
4  
(2.9; 0.9-
7.8) 
4: 1Cw, 1S, 
1M, 1Cob 
Abbas  
(2013)43 
Sudan 
(East) 
100 / 100 1.33 Media
n 2-8
(NR; 
0.5-
17) 
Mean 6.7; 
Median 5 
(4.5; 2-
20) 
TT 
NaCl/LIS
S 
4  
(4.0; 1.3-
11) 
4: 2K, 1C, 
1E 
Eldour  
(2015)44 
Sudan 
(East) 
210 / 210 1.44 Media
n 2 5 
(NR; 
2-20) 
≥2 units 
(NR; NR) 
NR 9  
(4.3; 2.1-
8.3) 
10: 5K, 2E, 
1c, 
1Kidd‡, 
1Leb 
Meda  
(2014)45 
Tanzani
a 
(East) 
365 / 365 0.81 Media
n 16 
(NR; 
0.5-
49) 
Mean 3.2; 
Median 2  
(NR; 1-
40) 
TT-NISS 15  
(4.1; 2.4-
6.8) 
63: 12K, 
9 a, 5Cob, 
4Fyb, 
4Kpa, 3D, 
3E, 3Cw, 
3Lua, 2C, 
2Leb, 2S, 
2s, 2Jkb, 
2P, 1M, 
1N, 1Jka, 
1PAN, 1UI 
Natukunda  
(2010)46 
Uganda 
(East) 
428 / 428 1.04 Media
n 12 
(NR; 
2-44) 
Median 3 
(NR; 2-
100) 
CGA-
LISS 
26 
(6.1; 4.1-
8.9) 
32: 10E, 
7D, 4S, 
2C, 2Jk
a
, 
2PAN, 1K, 
1Fya, 1Lea, 
1Cw, 1M 
Sekongo  
(2017)47 
Cote 
d’Ivoire 
(West) 
42 / 42 1.00 Mean 
4.5 
(NR; 
4-68) 
Mean 9, 
Median 6-
10 
(NR; 1-
22) 
CGA-
LISS 
 12  
(28.6; 16-
45) 
14: 6E, 4C, 
1D, 1e, S
UI Siransy  
(2018)48 
Cote 
d’Ivoire 
(West) 
31 / 27 0.82† Mean 
25.  
(NR; 
7-55) 
Mean 
5.7§ 
 (NR; 1-
>10) 
CGA 
(E-NR) 
5 
(18.5; 
7.0-39) 
3: 1C, 1E, 
Lea 
(Specificit
y was    
determined 
in two 
patients) 
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Boateng 
(2019)49 
Ghana 
(West) 
154 / 
154 
1.30 Median 
9 
(NR; 
1-50) 
Median 2-4 
(NR; 1->10) 
CGA-
LISS 
10 
(6.5; 
3.3-
11.9) 
13: 3D, 3M, 2E, 2C, 
1e, 1Cw, 1UI 
Diarra  
(2013)50 
Mali 
(West) 
133 / 90  0.73† Mean 
21† 
(NR; 
1-62) 
NR CGA  
(E-NR) 
4  
(4.4; 
1.4-12) 
4: 2C, 1D, 1c 
Kuliya-
Gwarzo 
(2005)51 
 
 
 
 
 
 ((2005) 
Nigeria 
(West) 
135 / 68 1.52 Mean 
4 
(6.5; 
NR) 
Median 1-5 
(NR; 1-10) 
TT-Alb 
and 
CGA 
6 
(8.8; 
3.6-
18.9) 
11: 2D, 2E, 1Kpb, 
1Jsb, 1Wra, 1Mg, 
1Vw, 1Dia, 1Goa 
Kangiwa  
(2015)52 
Nigeria 
(West) 
120 / 80 0.78 Median 
21† 
(NR; 
1-50) 
Mean 3 
(NR; 2-25) 
CGA-
LISS 
and 
enzymes 
5  
(18.8; 
11-29) 
13: 2E, 2c, 2e, 1D, 
1Fya, 1Fyb, 1k, 1Kpb, 
1Jsb, 1Lua  Ugwu  
(2015)53 
Nigeria 
(West) 
86 / 86 1.10 Mean 
26 
(7.4; 
18-48) 
≥2 units 
(NR; 2-NR) 
CGA-
LI S 
 
8 
(9.3; 
4.4-18) 
1: 3E, 2C, 1D, 1e, 
1k, 1Kpa, 1Jsb, 1Lub 
Adewoyin  
(2016)54 
Nigeria 
(West) 
55 / 41 1.39† Mean 
23† 
(12; 2-
51) 
Mean 4.5; 
Median 2 
(7.6; 1-55) 
TT  
(E-NR) 
 
(9.8; 
3.2-24) 
6: 2C, 2E, 1k, 1Lea 
N, number; SD, standard deviation; CI, confidence interval; CGA, column gel agglutination; 
LISS, low ionic strength solution; TT, tube technique; NISS, normal ionic strength solution; 
NR, not reported; E-NR, enhancer not reported; Alb, Albumin; UI, antibodies whose 
specificity could not be identified; PAN, pan-reactive antibody; †Including the non-
transfused patients because data for transfused patients were not reported separately; ‡Kidd 
specificity was not determined; §Mean number of transfusions per year. 
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Table 2: Specificities of the 206 red blood cell antibodies in transfused patients with sickle cell 
disease in sub-Sahara Africa. 
Blood group system 
(N, %)† 
RBC 
antigen 
N (%) 
Blood group system 
(N, %) 
RBC  
antigen 
N (%) 
Rhesus (95; 47.0) E 36 (17.5) Lewis (15; 7.4) Le
a
 12 (5.8) 
 D 22 (10.7)  Le
b
 3 (1.5) 
 C 21 (10.2) Duffy (7; 3.5) Fy
b
 5 (2.4) 
 C
w
 6 (2.9)  Fy
a
 2 (1.0) 
 e 5 (2.4) Kidd (6; 3.0) Jk
a
 3 (1.5) 
 c 4 (1.9)  Jk
b
 2 (1.0) 
 Go
a
 1 (0.5)  Kidd‡ 1 (0.5) 
Kell (31; 15.3) K 21 (10.2) Colton (6; 3.0) Co
b
 6 (2.9) 
 Kp
a
 5 (2.4) Lutheran (5; 2.5) Lu
a
 4 (1.9) 
 k 3 (1.5)  Lu
b
 1 (0.5) 
 Js
b
 3 (1.5) Globoside (2; 1.0) P 2 (1.0) 
 Kp
b
 2 (1.0) Wright (1; 0.5) Wr
a
 1 (0.5) 
MNSs (19; 9.4) S 8 (3.9) Diego (1: 0.5) Di
a
 1 (0.5) 
 M 6 (2.9)    
 s 2 (1.0) Unidentified (IUI)  12 (5.8) 
 N 1 (0.5) Pan-reactive (PAN)  3 (1.5) 
 M
g
 1 (0.5)    
 Vw 1 (0.5)    
†N, total number of antibodies against antigens from the blood group system; %, with total number of 
antibodies (n=206) as denominator. 
‡The Kidd antibody specificity was not reported. 
 
Highlights 
 
1. The pooled proportion of alloimmunisation in SCD in SSA is 7.4 (95% CI: 5.1–10.0) 
 
2. Almost 50% of antibody specificities were against D, C, E and K antigens 
 
3. Antibodies to low and high frequency antigens accounted for 29% of antibodies 
 
4. Studies did not consistently report factors that influence alloimmunisation 
 
5. SCD patients in SSA should be screened for RBC antibodies and IAT crossmatched  
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